eISSN 1738-8872
pISSN 1017-7825
pISSN 1017-7825
Table. 1.
Table. 1.
Vaccine candidates against SARS-CoV-2 infection and the stages of their clinical tests.
| Developer | Platform | Type of candidate vaccine | Current stage of clinical test |
|---|---|---|---|
| University of Oxford/AstraZeneca | Non-replicating viral vector | ChAdOx1-S | Phase 2b/3 |
| CanSino Biological Inc./Beijing Institute of Biotechnology | Non-replicating viral vector | Adenovirus Type 5 vector | Phase 2 |
| Moderna/NIAID | RNA | LNP-encapsulated mRNA | Phase 2 |
| Wuhan Institute of Biological Product/Sinopharm | Inactivated | Inactivated | Phase 1/2 |
| Beijing Institute of Biological Product/Sinopharm | Inactivated | Inactivated | Phase 1/2 |
| Sinovac | Inactivated | Inactivated + alum | Phase 1/2 |
| Novavax | Protein subunit | Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M | Phase 1/2 |
| BioNTech/Fosun Pharma/Pfizer | RNA | 3 LNP-mRNAs | Phase 1/2 |
| Institute of Medical Biology, Chinese Academy of Medical Sciences | Inactivated | Inactivated | Phase 1 |
| Inovio Pharmaceuticals | DNA | DNA plasmid vaccine with electroporation | Phase 1 |
J. Microbiol. Biotechnol. 2020;30:1109~1115 https://doi.org/10.4014/jmb.2006.06006
© J. Microbiol. Biotechnol.